Search

Your search keyword '"Stahlfeld, Charlotte N."' showing total 14 results
Start Over Author "Stahlfeld, Charlotte N."
14 results on '"Stahlfeld, Charlotte N."'

3. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Author

Zhao, Shuang G., Sperger, Jamie M., Schehr, Jennifer L., McKay, Rana R., Emamekhoo, Hamid, Singh, Anupama, Schultz, Zachery D., Bade, Rory M., Stahlfeld, Charlotte N., Gilsdorf, Cole S., Hernandez, Camila I., Wolfe, Serena K., Mayberry, Richel D., Krause, Hannah M., Bootsma, Matt, Helzer, Kyle T., Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Kyriakopoulos, Christos E., Kosoff, David, Wei, Xiao X., Floberg, John, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M., Huang, Wei, Beltran, Himisha, Choueiri, Toni K., Scher, Howard I., Rathkopf, Dana E., Halabi, Susan, Armstrong, Andrew J., Beebe, David J., Yu, Menggang, Sundling, Kaitlin E., Taplin, Mary-Ellen, and Lang, Joshua M.

Subjects
Prostate cancer -- Development and progression -- Prognosis, Tumor markers -- Genetic aspects -- Health aspects, Health care industry
Abstract

BACKGROUND. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer. METHODS. We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify the limit of quantification (LOQ) in cell lines, synthetic cDNA, and patient samples. We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor signaling inhibitors (ARSIs). We assessed a NEPC liquid biomarker via the presence of neuroendocrine markers and the absence of androgen receptor (AR) target genes. RESULTS. Using the analytical validation LOQ, liquid biomarker NEPC detection in the longitudinal cohort had a per- sample sensitivity of 51.35% and a specificity of 91.14%. However, when we incorporated the serial information from multiple liquid biopsies per patient, a unique aspect of this study, the per-patient predictions were 100% accurate, with a receiver- operatingcurve (ROC) AUC of 1. In the adenocarcinoma ARSI trials, the presence of neuroendocrine markers, even while AR target gene expression was retained, was a strong negative prognostic factor. CONCLUSION. Our analytically validated CTC biomarker can detect NEPC with high diagnostic accuracy when leveraging serial samples that are only feasible using liquid biopsies. Patients with expression of NE genes while retaining AR- target gene expression may indicate the transition to neuroendocrine differentiation, with clinical characteristics consistent with this phenotype. FUNDING. NIH (DP2 OD030734, 1UH2CA260389, R01CA247479, and P30 CA014520), Department of Defense (PC190039 and PC200334), and Prostate Cancer Foundation (Movember Foundation--PCF Challenge Award)., Introduction The majority of prostate cancers are histologically classified as adenocarcinomas. Prostate adenocarcinoma is driven by androgens, expresses prostate-specific antigen (PSA) and other androgen receptor (AR) target genes, and responds [...]

Published
2022
Full Text
View/download PDF

4. Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

Author

Sperger, Jamie M., primary, Helzer, Kyle T., primary, Stahlfeld, Charlotte N., primary, Jiang, Dawei, primary, Singh, Anupama, primary, Kaufmann, Katherine R., primary, Niles, David J., primary, Heninger, Erika, primary, Rydzewski, Nicholas R., primary, Wang, Liguo, primary, Wang, Liewei, primary, Yang, Rendong, primary, Ren, Yanan, primary, Engle, Jonathan W., primary, Huang, Peng, primary, Kyriakopoulos, Christos E., primary, Slovin, Susan F., primary, Soule, Howard R., primary, Zhao, Shuang G., primary, Kohli, Manish, primary, Tagawa, Scott T., primary, Cai, Weibo, primary, Dehm, Scott M., primary, and Lang, Joshua M., primary

Published
2023
Full Text
View/download PDF

5. Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

Author

Sperger, Jamie M., primary, Helzer, Kyle T., additional, Stahlfeld, Charlotte N., additional, Jiang, Dawei, additional, Singh, Anupama, additional, Kaufmann, Katherine R., additional, Niles, David J., additional, Heninger, Erika, additional, Rydzewski, Nicholas R., additional, Wang, Liguo, additional, Wang, Liewei, additional, Yang, Rendong, additional, Ren, Yanan, additional, Engle, Jonathan W., additional, Huang, Peng, additional, Kyriakopoulos, Christos E., additional, Slovin, Susan F., additional, Soule, Howard R., additional, Zhao, Shuang G., additional, Kohli, Manish, additional, Tagawa, Scott T., additional, Cai, Weibo, additional, Dehm, Scott M., additional, and Lang, Joshua M., additional

Published
2023
Full Text
View/download PDF

6. Additional file 1 of SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples

Author

Rodems, Tamara S., Juang, Duane S., Stahlfeld, Charlotte N., Gilsdorf, Cole S., Krueger, Tim E. G., Heninger, Erika, Zhao, Shuang G., Sperger, Jamie M., Beebe, David J., Haffner, Michael C., and Lang, Joshua M.

Subjects
urologic and male genital diseases, neoplasms
Abstract

Additional file 1. Figure S1: Primer locations and genomic context for GSTP1, RASSF1, APC, and RARB. Figure S2: ROC curves for GSTP1 detection from non-single cell sample groups. Figure S3: Detection of GSTP1 promoter in additional dilutions of WBCs. Figure S4: Effect of non-methylation-sensitive enzyme digestion on GSTP1 enrichment. Figure S5: Analysis of preamplification for GSTP1, RASSF1, APC, and RARB.

Published
2022
Full Text
View/download PDF

7. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

Author

Sperger, Jamie M., primary, Emamekhoo, Hamid, additional, McKay, Rana R., additional, Stahlfeld, Charlotte N., additional, Singh, Anupama, additional, Chen, Xinyi E., additional, Kwak, Lucia, additional, Gilsdorf, Cole S., additional, Wolfe, Serena K., additional, Wei, Xiao X., additional, Silver, Rebecca, additional, Zhang, Zhenwei, additional, Morris, Michael J., additional, Bubley, Glenn, additional, Feng, Felix Y., additional, Scher, Howard I., additional, Rathkopf, Dana, additional, Dehm, Scott M., additional, Choueiri, Toni K., additional, Halabi, Susan, additional, Armstrong, Andrew J., additional, Wyatt, Alexander W., additional, Taplin, Mary-Ellen, additional, Zhao, Shuang G., additional, and Lang, Joshua M., additional

Published
2021
Full Text
View/download PDF

10. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma

Author

Bade, Rory M., primary, Schehr, Jennifer L., additional, Emamekhoo, Hamid, additional, Gibbs, Benjamin K., additional, Rodems, Tamara S., additional, Mannino, Matthew C., additional, Desotelle, Joshua A., additional, Heninger, Erika, additional, Stahlfeld, Charlotte N., additional, Sperger, Jamie M., additional, Singh, Anupama, additional, Wolfe, Serena K., additional, Niles, David J., additional, Arafat, Waddah, additional, Steinharter, John A., additional, Jason Abel, E., additional, Beebe, David J., additional, Wei, Xiao X., additional, McKay, Rana R., additional, Choueri, Toni K., additional, and Lang, Joshua M., additional

Published
2021
Full Text
View/download PDF

11. supplemental_material_for_SASCA_by_Tokar_and_Stahlfeld_et_al – Supplemental material for Pairing Microwell Arrays with an Affordable, Semiautomated Single-Cell Aspirator for the Interrogation of Circulating Tumor Cell Heterogeneity

Author

Tokar, Jacob J., Stahlfeld, Charlotte N., Sperger, Jamie M., Niles, David J., Beebe, David J., Lang, Joshua M., and Warrick, Jay W.

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, supplemental_material_for_SASCA_by_Tokar_and_Stahlfeld_et_al for Pairing Microwell Arrays with an Affordable, Semiautomated Single-Cell Aspirator for the Interrogation of Circulating Tumor Cell Heterogeneity by Jacob J. Tokar, Charlotte N. Stahlfeld, Jamie M. Sperger, David J. Niles, David J. Beebe, Joshua M. Lang and Jay W. Warrick in SLAS Technology

Published
2020
Full Text
View/download PDF

12. Abstract B40: Analytical validation and initial clinical utility of multianalyte transcriptomic biomarker profiling of circulating tumor cells using automated exclusion-based sample preparation technology

Author

Schultz, Zachery D., primary, Schehr, Jennifer L., additional, Bade, Rory M., additional, Morgan, Molly M., additional, Gill, Madalyn S., additional, Pezzi, Hannah M., additional, Sperger, Jaime M., additional, Stahlfeld, Charlotte N., additional, Singh, Anupama, additional, Warrick, Jay W., additional, Beebe, David J., additional, and Lang, Joshua M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results